leflunomide has been researched along with Disease Exacerbation in 42 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy and safety of leflunomide (LEF)-anti-TNF-alpha combination therapy to methotrexate (MTX)-anti-TNF-alpha combination therapy in a group of patients with active rheumatoid arthritis (RA)." | 9.14 | Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. ( Baldi, C; De Stefano, R; Frati, E; Galeazzi, M; Hammoud, M; Menza, L; Nargi, F, 2010) |
| "To evaluate the efficacy and safety of leflunomide in the treatment of proliferative lupus nephritis, a prospective multi-centre observational study was conducted." | 9.13 | Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. ( Cai, GY; Chen, XM; Cui, TG; Hou, FF; Jiang, ZP; Li, YN; Lu, FM; Mei, CL; Ni, ZH; Qian, JQ; Wang, GB; Wang, HY; Wang, YH; Xu, FF; Yu, XQ; Zhang, FS; Zhao, MH; Zhao, XZ; Zhu, TY; Zou, WZ, 2008) |
| "To study effects of leflunomide on inflammatory and destructive processes in patients with early rheumatoid arthritis (RA)." | 9.12 | [An antidestructive effect of leflunomide in early rheumatoid arthritis]. ( Aleksandrova, EN; Balabanova, RM; Kashevarov, RIu; Oliunin, IuA; Smirnov, AV, 2006) |
| " This study evaluates the efficacy and safety of leflunomide and sulfasalazine in rheumatoid arthritis over a two year follow up period." | 9.09 | Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. ( Kalden, JR; Kvien, TK; Larsen, A; Loew-Friedrich, I; Nash, P; Oed, C; Schattenkirchner, M; Scott, DL; Smolen, JS; van de Putte, LB, 2001) |
| "Radiographic disease progression with leflunomide and sulfasalazine treatment was assessed in rheumatoid arthritis patients in a double-blind trial that was placebo controlled for the first 6 months." | 9.09 | Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. ( Kvien, TK; Larsen, A; Oed, C; Rau, R; Rosenburg, R; Rozman, B; Schattenkirchner, M; Scott, DL; Smolen, JS; Tikly, M; Westhovens, R, 2001) |
| "To compare the clinical efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis (RA)." | 9.09 | A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. ( Bjorneboe, O; Breedveld, FC; Dahl, R; Dawes, PT; Emery, P; Gömör, B; Horslev-Petersen, K; Kaltwasser, JP; Lemmel, EM; Loew-Friedrich, I; Molloy, M; Nordström, D; Oed, C; Rodriguez De La Serna, A; Rosenburg, R; Tikly, M; Van Den Bosch, F, 2000) |
| "Leflunomide was more effective than placebo in treatment of rheumatoid arthritis and showed similar efficacy to sulphasalazine." | 9.09 | Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. ( Kalden, JR; Kvien, TK; Larsen, A; Loew-Friedrich, I; Oed, C; Rosenburg, R; Rozman, B; Scott, DL; Smolen, JS, 1999) |
| "To assess the effectiveness, safety and cost implications of leflunomide treatment for rheumatoid arthritis." | 8.80 | Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications. ( Debroe, S; Hewitson, PJ; McBride, A; Milne, R, 2000) |
| "To evaluate the efficacy and safety of leflunomide (LEF) as induction treatment in a series of Takayasu arteritis (TA) patients based on a Chinese cohort." | 7.96 | Efficacy and safety of leflunomide treatment in Takayasu arteritis: Case series from the East China cohort. ( Cui, X; Dai, X; Ding, J; Dong, Z; Feng, X; Fu, W; Jiang, L; Li, S; Lin, H; Lin, J; Lu, Y; Lv, P; Ma, L; Sun, X; Tan, W; Wang, C; Wang, L; Wang, Y; Wu, M; Wu, R; Yang, C; Zhang, L; Zhang, Z; Zhou, Z; Zou, Y, 2020) |
| "We retrospectively investigated the inhibitory effect on radiographic joint damage (RJD) for non-biological disease-modifying antirheumatic drug (non-bioDMARD) monotherapy or methotrexate (MTX) combination therapy for rheumatoid arthritis (RA) in the disease activity score with 28 joint counts with erythrocyte sedimentation rate (DAS28) remission." | 7.81 | Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice. ( Baba, H; Fukai, R; Ito, H; Katayama, K; Okubo, T; Sato, T, 2015) |
| "To compare the effectiveness and safety of a combination of rituximab (RTX) with either methotrexate (MTX) or leflunomide (LEF) in the treatment of patients with active rheumatoid arthritis (RA) and inadequate response to anti-tumor necrosis factor agents or traditional disease-modifying antirheumatic drugs (DMARD) in a real-world setting." | 7.77 | Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. ( Díaz-López, C; Díaz-Torné, C; Hernández, MV; Narváez, J; Nolla, JM; Rodriguez de la Serna, A; Ros, S; Ruiz, JM; Sanmartí, R; Torrente-Segarra, V, 2011) |
| "We retrospectively compared treatment impact with leflunomide (LEF) or methotrexate (MTX) on retarding joint damage and clinical symptom including a 28-joint-count Disease Activity Score/erythrocyte sedimentation rate (DAS28-ESR) between two similar groups in patients with rheumatoid arthritis (RA) over an approximately 3-year treatment." | 7.75 | Long-term efficacy of leflunomide on disease activity and inhibition of joint damage: retrospective comparison with methotrexate for Japanese rheumatoid arthritis patients. ( Katayama, K; Matsuno, T, 2009) |
| "Randomised trials have demonstrated that the efficacy of anti-tumour necrosis factor (TNF) agents is significantly increased by concomitant methotrexate (MTX) in rheumatoid arthritis (RA)." | 7.75 | The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. ( Dehler, S; Finckh, A; Gabay, C, 2009) |
| "Treatment with leflunomide was associated with increased levels of carbonyl protein, and lowered levels in TRAP and UA, while the NOx/TRAP ratio further increased." | 5.48 | Metabolic syndrome and the decreased levels of uric acid by leflunomide favor redox imbalance in patients with rheumatoid arthritis. ( Alfieri, DF; Costa, NT; de Medeiros, FA; de Sá, MC; Dichi, I; Iriyoda, TMV; Lozovoy, MAB; Maes, M; Micheletti, PL; Reiche, EMV; Scavuzzi, BM; Sekiguchi, BA; Simão, ANC, 2018) |
| "To compare the efficacy and safety of leflunomide (LEF)-anti-TNF-alpha combination therapy to methotrexate (MTX)-anti-TNF-alpha combination therapy in a group of patients with active rheumatoid arthritis (RA)." | 5.14 | Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. ( Baldi, C; De Stefano, R; Frati, E; Galeazzi, M; Hammoud, M; Menza, L; Nargi, F, 2010) |
| "To evaluate the efficacy and safety of leflunomide in the treatment of proliferative lupus nephritis, a prospective multi-centre observational study was conducted." | 5.13 | Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. ( Cai, GY; Chen, XM; Cui, TG; Hou, FF; Jiang, ZP; Li, YN; Lu, FM; Mei, CL; Ni, ZH; Qian, JQ; Wang, GB; Wang, HY; Wang, YH; Xu, FF; Yu, XQ; Zhang, FS; Zhao, MH; Zhao, XZ; Zhu, TY; Zou, WZ, 2008) |
| "To study effects of leflunomide on inflammatory and destructive processes in patients with early rheumatoid arthritis (RA)." | 5.12 | [An antidestructive effect of leflunomide in early rheumatoid arthritis]. ( Aleksandrova, EN; Balabanova, RM; Kashevarov, RIu; Oliunin, IuA; Smirnov, AV, 2006) |
| "Leflunomide was more effective than placebo in treatment of rheumatoid arthritis and showed similar efficacy to sulphasalazine." | 5.09 | Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. ( Kalden, JR; Kvien, TK; Larsen, A; Loew-Friedrich, I; Oed, C; Rosenburg, R; Rozman, B; Scott, DL; Smolen, JS, 1999) |
| "To compare the clinical efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis (RA)." | 5.09 | A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. ( Bjorneboe, O; Breedveld, FC; Dahl, R; Dawes, PT; Emery, P; Gömör, B; Horslev-Petersen, K; Kaltwasser, JP; Lemmel, EM; Loew-Friedrich, I; Molloy, M; Nordström, D; Oed, C; Rodriguez De La Serna, A; Rosenburg, R; Tikly, M; Van Den Bosch, F, 2000) |
| "Radiographic disease progression with leflunomide and sulfasalazine treatment was assessed in rheumatoid arthritis patients in a double-blind trial that was placebo controlled for the first 6 months." | 5.09 | Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. ( Kvien, TK; Larsen, A; Oed, C; Rau, R; Rosenburg, R; Rozman, B; Schattenkirchner, M; Scott, DL; Smolen, JS; Tikly, M; Westhovens, R, 2001) |
| " This study evaluates the efficacy and safety of leflunomide and sulfasalazine in rheumatoid arthritis over a two year follow up period." | 5.09 | Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. ( Kalden, JR; Kvien, TK; Larsen, A; Loew-Friedrich, I; Nash, P; Oed, C; Schattenkirchner, M; Scott, DL; Smolen, JS; van de Putte, LB, 2001) |
| "Recurrences of COVID-19 were observed in a patient with long-term usage of hydroxychloroquine, leflunomide, and glucocorticoids due to her 30-year history of rheumatoid arthritis (RA)." | 5.05 | A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab. ( Cai, S; Dong, L; Li, M; Sun, W, 2020) |
| "To assess the effectiveness, safety and cost implications of leflunomide treatment for rheumatoid arthritis." | 4.80 | Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications. ( Debroe, S; Hewitson, PJ; McBride, A; Milne, R, 2000) |
| "To evaluate the efficacy and safety of leflunomide (LEF) as induction treatment in a series of Takayasu arteritis (TA) patients based on a Chinese cohort." | 3.96 | Efficacy and safety of leflunomide treatment in Takayasu arteritis: Case series from the East China cohort. ( Cui, X; Dai, X; Ding, J; Dong, Z; Feng, X; Fu, W; Jiang, L; Li, S; Lin, H; Lin, J; Lu, Y; Lv, P; Ma, L; Sun, X; Tan, W; Wang, C; Wang, L; Wang, Y; Wu, M; Wu, R; Yang, C; Zhang, L; Zhang, Z; Zhou, Z; Zou, Y, 2020) |
| "We retrospectively investigated the inhibitory effect on radiographic joint damage (RJD) for non-biological disease-modifying antirheumatic drug (non-bioDMARD) monotherapy or methotrexate (MTX) combination therapy for rheumatoid arthritis (RA) in the disease activity score with 28 joint counts with erythrocyte sedimentation rate (DAS28) remission." | 3.81 | Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice. ( Baba, H; Fukai, R; Ito, H; Katayama, K; Okubo, T; Sato, T, 2015) |
| "To compare the effectiveness and safety of a combination of rituximab (RTX) with either methotrexate (MTX) or leflunomide (LEF) in the treatment of patients with active rheumatoid arthritis (RA) and inadequate response to anti-tumor necrosis factor agents or traditional disease-modifying antirheumatic drugs (DMARD) in a real-world setting." | 3.77 | Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. ( Díaz-López, C; Díaz-Torné, C; Hernández, MV; Narváez, J; Nolla, JM; Rodriguez de la Serna, A; Ros, S; Ruiz, JM; Sanmartí, R; Torrente-Segarra, V, 2011) |
| "We retrospectively compared treatment impact with leflunomide (LEF) or methotrexate (MTX) on retarding joint damage and clinical symptom including a 28-joint-count Disease Activity Score/erythrocyte sedimentation rate (DAS28-ESR) between two similar groups in patients with rheumatoid arthritis (RA) over an approximately 3-year treatment." | 3.75 | Long-term efficacy of leflunomide on disease activity and inhibition of joint damage: retrospective comparison with methotrexate for Japanese rheumatoid arthritis patients. ( Katayama, K; Matsuno, T, 2009) |
| "Randomised trials have demonstrated that the efficacy of anti-tumour necrosis factor (TNF) agents is significantly increased by concomitant methotrexate (MTX) in rheumatoid arthritis (RA)." | 3.75 | The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. ( Dehler, S; Finckh, A; Gabay, C, 2009) |
| "Patients with primary IgA nephropathy, confirmed by renal biopsy, were recruited for this study." | 2.80 | Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy. ( Chen, F; Cheng, G; Fang, Y; Guo, Y; Li, H; Liu, D; Liu, F; Liu, L; Liu, Z; Margetts, P; Tang, L; Zhao, Z, 2015) |
| "This paper reviews recent approaches to treatment of early rheumatoid arthritis (RA) with disease-modifying antirheumatic drugs (DMARDs)." | 2.44 | Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs. ( Sizova, L, 2008) |
| " This study compared groups treated with high-dose methotrexate (MTX)/leflunomide (LEF) and CP-25 combined with low-dose MTX/LEF in an adjuvant-induced arthritis (AA) rat model and investigated possible mechanisms." | 1.51 | CP-25 combined with MTX/ LEF ameliorates the progression of adjuvant-induced arthritis by the inhibition on GRK2 translocation. ( Chang, Y; Jia, X; Wang, C; Wei, W; Wu, Y; Yang, X; Zhang, L; Zhao, Y, 2019) |
| "Treatment with leflunomide was associated with increased levels of carbonyl protein, and lowered levels in TRAP and UA, while the NOx/TRAP ratio further increased." | 1.48 | Metabolic syndrome and the decreased levels of uric acid by leflunomide favor redox imbalance in patients with rheumatoid arthritis. ( Alfieri, DF; Costa, NT; de Medeiros, FA; de Sá, MC; Dichi, I; Iriyoda, TMV; Lozovoy, MAB; Maes, M; Micheletti, PL; Reiche, EMV; Scavuzzi, BM; Sekiguchi, BA; Simão, ANC, 2018) |
| "IgA nephropathy is the most common primary glomerulonephritis and one of the leading causes of end-stage renal disease." | 1.46 | Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy. ( Cao, L; Che, X; Fang, W; Gu, L; Min, L; Mou, S; Ni, Z; Qian, J; Wang, L; Wang, Q; Yu, Z; Yuan, J; Zhang, M; Zhou, W; Zhu, M, 2017) |
| "Episcleritis and scleritis are relatively rare ocular diseases, which are commonly associated with rheumatic diseases including systemic lupus erythematosus (SLE)." | 1.43 | [Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus]. ( Jia, Y; Miao, H; Wang, L; Yang, Y; Zhang, XY; Zhou, YS, 2016) |
| "The radiological assessment of disease progression was estimated by the Sharp Score." | 1.42 | Is there a role for Digital X-ray Radiogrammetry as surrogate marker for radiological progression and imaging of structural integrity in rheumatoid arthritis? ( Böttcher, J; Hansch, A; Oelzner, P; Pfeil, A; Renz, DM; Wolf, G, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.38) | 18.2507 |
| 2000's | 22 (52.38) | 29.6817 |
| 2010's | 17 (40.48) | 24.3611 |
| 2020's | 2 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, S | 1 |
| Sun, W | 1 |
| Li, M | 1 |
| Dong, L | 1 |
| Min, L | 1 |
| Wang, Q | 1 |
| Cao, L | 1 |
| Zhou, W | 1 |
| Yuan, J | 1 |
| Zhang, M | 1 |
| Che, X | 1 |
| Mou, S | 1 |
| Fang, W | 1 |
| Gu, L | 1 |
| Zhu, M | 1 |
| Wang, L | 3 |
| Yu, Z | 1 |
| Qian, J | 1 |
| Ni, Z | 1 |
| Costa, NT | 1 |
| Scavuzzi, BM | 1 |
| Iriyoda, TMV | 1 |
| Lozovoy, MAB | 1 |
| Alfieri, DF | 1 |
| de Medeiros, FA | 1 |
| de Sá, MC | 1 |
| Micheletti, PL | 1 |
| Sekiguchi, BA | 1 |
| Reiche, EMV | 1 |
| Maes, M | 1 |
| Simão, ANC | 1 |
| Dichi, I | 1 |
| Yang, X | 1 |
| Zhao, Y | 1 |
| Jia, X | 1 |
| Wang, C | 2 |
| Wu, Y | 1 |
| Zhang, L | 2 |
| Chang, Y | 1 |
| Wei, W | 1 |
| Cui, X | 1 |
| Dai, X | 1 |
| Ma, L | 1 |
| Yang, C | 1 |
| Tan, W | 1 |
| Zhang, Z | 1 |
| Feng, X | 1 |
| Wu, R | 1 |
| Zou, Y | 1 |
| Zhou, Z | 1 |
| Lu, Y | 1 |
| Wang, Y | 1 |
| Wu, M | 1 |
| Li, S | 1 |
| Lin, H | 1 |
| Dong, Z | 1 |
| Fu, W | 1 |
| Sun, X | 1 |
| Ding, J | 1 |
| Lv, P | 1 |
| Lin, J | 1 |
| Jiang, L | 1 |
| Aletaha, D | 1 |
| Alasti, F | 1 |
| Smolen, JS | 5 |
| Rutanen, J | 1 |
| Kononoff, A | 1 |
| Arstila, L | 1 |
| Elfving, P | 1 |
| Koskela, H | 1 |
| Kaipiainen-Seppänen, O | 1 |
| Katayama, K | 2 |
| Okubo, T | 1 |
| Sato, T | 1 |
| Ito, H | 1 |
| Fukai, R | 1 |
| Baba, H | 1 |
| Cheng, G | 1 |
| Liu, D | 1 |
| Margetts, P | 1 |
| Liu, L | 1 |
| Zhao, Z | 1 |
| Liu, Z | 1 |
| Tang, L | 1 |
| Fang, Y | 1 |
| Li, H | 1 |
| Guo, Y | 1 |
| Chen, F | 1 |
| Liu, F | 1 |
| van Nies, JA | 1 |
| Tsonaka, R | 1 |
| Gaujoux-Viala, C | 1 |
| Fautrel, B | 2 |
| van der Helm-van Mil, AH | 1 |
| Alibaz-Oner, F | 1 |
| Direskeneli, H | 1 |
| Pfeil, A | 1 |
| Oelzner, P | 1 |
| Renz, DM | 1 |
| Hansch, A | 1 |
| Wolf, G | 1 |
| Böttcher, J | 1 |
| Yang, Y | 1 |
| Jia, Y | 1 |
| Miao, H | 1 |
| Zhou, YS | 1 |
| Zhang, XY | 1 |
| Sizova, L | 1 |
| Wang, HY | 1 |
| Cui, TG | 1 |
| Hou, FF | 1 |
| Ni, ZH | 1 |
| Chen, XM | 1 |
| Lu, FM | 1 |
| Xu, FF | 1 |
| Yu, XQ | 1 |
| Zhang, FS | 1 |
| Zhao, XZ | 1 |
| Zhao, MH | 1 |
| Wang, GB | 1 |
| Qian, JQ | 1 |
| Cai, GY | 1 |
| Zhu, TY | 1 |
| Wang, YH | 1 |
| Jiang, ZP | 1 |
| Li, YN | 1 |
| Mei, CL | 1 |
| Zou, WZ | 1 |
| Yukawa, N | 1 |
| Mimori, T | 1 |
| Canivet, C | 1 |
| Rostaing, L | 1 |
| Galvani, S | 1 |
| Böhler, T | 1 |
| Gandia, P | 1 |
| Mengelle, C | 1 |
| Guilbeau-Frugier, C | 1 |
| Thomsen, M | 1 |
| Salvayre, R | 1 |
| Negre-Salvayre, A | 1 |
| Kamar, N | 1 |
| Matsuno, T | 1 |
| De Stefano, R | 1 |
| Frati, E | 1 |
| Nargi, F | 1 |
| Baldi, C | 1 |
| Menza, L | 1 |
| Hammoud, M | 1 |
| Galeazzi, M | 1 |
| Pettersson, T | 1 |
| Karjalainen, A | 1 |
| Narváez, J | 1 |
| Díaz-Torné, C | 1 |
| Ruiz, JM | 1 |
| Hernández, MV | 1 |
| Torrente-Segarra, V | 1 |
| Ros, S | 1 |
| Rodriguez de la Serna, A | 2 |
| Díaz-López, C | 1 |
| Sanmartí, R | 1 |
| Nolla, JM | 1 |
| Sakellariou, GT | 1 |
| Sayegh, FE | 1 |
| Anastasilakis, AD | 1 |
| Kapetanos, GA | 1 |
| Granger, B | 1 |
| Combe, B | 1 |
| Saraux, A | 1 |
| Guillemin, F | 1 |
| Le Loet, X | 1 |
| Brandt-Jürgens, J | 1 |
| Breedveld, FC | 2 |
| Schiff, MH | 1 |
| Kalden, JR | 3 |
| Emery, P | 2 |
| Eberl, G | 1 |
| van Riel, PL | 1 |
| Tugwell, P | 1 |
| Ory, PA | 1 |
| van der Heijde, D | 1 |
| Kalden, J | 1 |
| Scott, D | 1 |
| Smolen, J | 1 |
| Strand, V | 2 |
| van der Heijde, DM | 1 |
| Issa, SN | 1 |
| Ruderman, EM | 1 |
| Kopp, HG | 1 |
| Moerike, K | 1 |
| Kanz, L | 1 |
| Hartmann, JT | 1 |
| Davis, IC | 1 |
| Lazarowski, ER | 1 |
| Hickman-Davis, JM | 1 |
| Fortenberry, JA | 1 |
| Chen, FP | 1 |
| Zhao, X | 1 |
| Sorscher, E | 1 |
| Graves, LM | 1 |
| Sullender, WM | 1 |
| Matalon, S | 1 |
| Balabanova, RM | 1 |
| Kashevarov, RIu | 1 |
| Oliunin, IuA | 1 |
| Smirnov, AV | 1 |
| Aleksandrova, EN | 1 |
| Suzuki, Y | 1 |
| Wakabayashi, T | 1 |
| Saito, E | 1 |
| Suwa, A | 1 |
| Finckh, A | 1 |
| Dehler, S | 1 |
| Gabay, C | 1 |
| Kremer, AE | 1 |
| Budenhofer, U | 1 |
| Beuers, U | 1 |
| Rust, C | 1 |
| Scott, DL | 3 |
| Rozman, B | 2 |
| Kvien, TK | 3 |
| Larsen, A | 3 |
| Loew-Friedrich, I | 4 |
| Oed, C | 4 |
| Rosenburg, R | 3 |
| Sharp, JT | 1 |
| Leung, H | 1 |
| Hurley, F | 1 |
| Lemmel, EM | 1 |
| Kaltwasser, JP | 1 |
| Dawes, PT | 1 |
| Gömör, B | 1 |
| Van Den Bosch, F | 1 |
| Nordström, D | 1 |
| Bjorneboe, O | 1 |
| Dahl, R | 1 |
| Horslev-Petersen, K | 1 |
| Molloy, M | 1 |
| Tikly, M | 2 |
| Vlassenko, AG | 1 |
| Thiessen, B | 1 |
| Beattie, BJ | 1 |
| Malkin, MG | 1 |
| Blasberg, RG | 1 |
| Hewitson, PJ | 1 |
| Debroe, S | 1 |
| McBride, A | 1 |
| Milne, R | 1 |
| Schattenkirchner, M | 2 |
| Rau, R | 1 |
| Westhovens, R | 1 |
| van de Putte, LB | 1 |
| Nash, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Observational Study of Hair Fall in Rheumatoid Arthritis Patients Treated With Low Dose Methotrexate[NCT02591823] | 80 participants (Anticipated) | Observational | 2015-10-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for leflunomide and Disease Exacerbation
| Article | Year |
|---|---|
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.
Topics: Aged; Anti-Bacterial Agents; Antifungal Agents; Antirheumatic Agents; Antiviral Agents; Arthritis, R | 2020 |
Update on Takayasu's arteritis.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Biological Products; Biomarkers; Diagnos | 2015 |
Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Disea | 2008 |
[Effect of disease modifying anti-rheumatic drugs on radiographic progression in rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Cysteine; Disease Progression; Drug Thera | 2009 |
[Diagnosis and management of small vessel vasculitides].
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal; Antibodies, Mono | 2010 |
Interpreting radiographic data in rheumatoid arthritis.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progressi | 2003 |
Overview of radiologic efficacy of new treatments.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Disea | 2004 |
Damage control in rheumatoid arthritis. Hard-hitting, early treatment is crucial to curbing joint destruction.
Topics: Arthritis, Rheumatoid; Azathioprine; Disease Progression; Humans; Hydroxychloroquine; Immunologic Fa | 2004 |
[Inhibition of radiographic progression in rheumatoid arthritis by anti-rheumatic drugs (DMARDs)].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Cyclosporine; Disease Progres | 2007 |
Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Cost | 2000 |
10 trials available for leflunomide and Disease Exacerbation
| Article | Year |
|---|---|
Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biomarkers; China; Clopidogrel; Creatinine; Disease | 2015 |
Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study.
Topics: Adolescent; Adult; Aged; Biopsy; Disease Progression; Female; Humans; Immunosuppressive Agents; Isox | 2008 |
Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Autoimmunity; Disease Progression; Drug Th | 2010 |
Long term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Disease Progression; Humans; Immunos | 2004 |
[An antidestructive effect of leflunomide in early rheumatoid arthritis].
Topics: Adjuvants, Immunologic; Adult; Arthritis, Rheumatoid; Disease Progression; Drug Administration Sched | 2006 |
Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.
Topics: Algorithms; Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; | 1999 |
Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progre | 2000 |
A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Co | 2000 |
Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Disease Progression; Do | 2001 |
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; C | 2001 |
22 other studies available for leflunomide and Disease Exacerbation
| Article | Year |
|---|---|
Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy.
Topics: Adrenal Cortex Hormones; Adult; Biomarkers; Blood Pressure; Disease Progression; Drug Therapy, Combi | 2017 |
Metabolic syndrome and the decreased levels of uric acid by leflunomide favor redox imbalance in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Advanced Oxidation Protein Products; Aged; Antirheumatic Agents; Arthritis, Rheum | 2018 |
CP-25 combined with MTX/ LEF ameliorates the progression of adjuvant-induced arthritis by the inhibition on GRK2 translocation.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Cells, Cultured; Disease Progression; Drug T | 2019 |
Efficacy and safety of leflunomide treatment in Takayasu arteritis: Case series from the East China cohort.
Topics: Adolescent; Adult; China; Cyclophosphamide; Disease Progression; Female; Humans; Immunosuppressive A | 2020 |
Chronicity of rheumatoid arthritis affects the responsiveness of physical function, but not of disease activity measures in rheumatoid arthritis clinical trials.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Ag | 2015 |
Five cases of interstitial lung disease after leflunomide was combined with methotrexate therapy.
Topics: Aged; Arthritis, Rheumatoid; Disease Progression; Drug Interactions; Drug Therapy, Combination; Fema | 2014 |
Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combina | 2015 |
Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts.
Topics: Adult; Aged; Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; Autoantibodies; Cohort S | 2015 |
Is there a role for Digital X-ray Radiogrammetry as surrogate marker for radiological progression and imaging of structural integrity in rheumatoid arthritis?
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Bone Density; Disease Progre | 2015 |
[Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus].
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antinucle | 2016 |
Polyoma BK virus-associated nephropathy in kidney-transplant patients: Effects of leflunomide on T-cell functions and disease outcome.
Topics: Adult; Aged; Antigens, CD; BK Virus; Cell Proliferation; Disease Progression; Female; Follow-Up Stud | 2009 |
Long-term efficacy of leflunomide on disease activity and inhibition of joint damage: retrospective comparison with methotrexate for Japanese rheumatoid arthritis patients.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Chi-Square Distribution; Disease P | 2009 |
Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; Di | 2011 |
Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate.
Topics: Adult; Antirheumatic Agents; Arthritis, Psoriatic; Disease Progression; Drug Therapy, Combination; F | 2013 |
Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; C-Reactive Protein; Cohort Studi | 2012 |
[Leflunomide and TNF inhibitors. Experiences from precription recourse proceedings].
Topics: Adalimumab; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Disease Progression; Drug | 2013 |
A simplified disease activity index for rheumatoid arthritis for use in clinical practice.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein; Clinical Trials, | 2003 |
Leflunomide and peripheral neuropathy: a potential interaction between uracil/tegafur and leflunomide.
Topics: Administration, Oral; Aged; Arthritis, Rheumatoid; Comorbidity; Disease Progression; Drug Administra | 2005 |
Leflunomide prevents alveolar fluid clearance inhibition by respiratory syncytial virus.
Topics: Animals; Antiviral Agents; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Disease Progression | 2006 |
The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study.
Topics: Aged; Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Confounding F | 2009 |
[A 47-year-old dog breeder with chronic polyarthritis, weight loss and high fever].
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit | 2008 |
Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biologica | 2000 |